Shire plc: PharmaVitae Report
Datamonitor, July 2012, Pages: 41
Analysis of Shire's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017
This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs
Scope
- Gain insight into Shire's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
- Shire exhibited rapid revenue growth over 2005–11, despite a dip in sales over 2008–09 caused by generic erosion to Adderall XR. Shire’s impressive performance has been driven not only by its effective lifecycle management strategy, but also by strong uptake of its Human Genetic Therapies portfolio.
- During the forecast period, Shire is expected to see a slowdown in sales growth. This is largely attributable to the absence of new product launches in the near future, given that its R&D pipeline is largely based on early-stage products.
Reasons to Purchase
- Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector
- Assess how successful Shire will be in diversifying its business focus and reducing its reliance on the US ADHD market
- See how Shire has developed a portfolio of products indicated for highly symptomatic diseases in an effort to build sustainable growth
SCOPE OF SHIRE ANALYSIS
- PharmaVitae Explorer database
- Analysis structure
- - Strategic Insight
- - Company Overview
- - Operating Performance Analysis
EXECUTIVE SUMMARY
- Key findings
- Shire prescription pharmaceutical sales outlook
- Shire financial outlook
- SWOT analysis
- - Weaknesses
- - Opportunities
- - Threats
STRATEGIC INSIGHT
- Key findings
- Launch/core/expiry analysis
- Strategic insight
- - Despite a declining focus in CNS, this therapy area will continue to generate the majority of sales out to 2017
- - Niche disorders to be Shire’s other key area of sales growth
- - Generic competition in CNS market justifies switch in focus to niche disorders
CORPORATE STRUCTURE
- Key findings
- Background
- Corporate structure
- - Human Genetic Therapies
- - Specialty Pharmaceuticals
- - Regenerative Medicine
- M&A history
- - M&A strategy
OPERATING PERFORMANCE
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2005–11
- Operating costs and profit analysis
- - Operating costs and profit analysis, 2005–11
- - Operating cost ratio and profit margin analysis, 2005–11
- - Operating cost ratio and profit margin analysis, 2011–17
- - Operating costs and profit analysis, 2011–17
APPENDIX
- References
- Exchange rates
TABLES
Table: Datamonitor’s established pharmaceutical company coverage, 2012
Table: Shire – key product overview ($m), 2011–17 Table: Shire’s financial performance ($m), 2011–17
Table: Shire’s launch, core, and expiry portfolio overview ($m), 2011–17
Table: The Gaucher disease market, 2012
Table: Shire’s key merger and acquisition deals, 1995-12
Table: Total Shire sales by business unit ($m), 2005–11
Table: Shire’s operating revenue/cost analysis ($m), 2005–11
Table: Shire’s operating cost ratio analysis (percentage of total revenues), 2005–11
Table: Shire’s operating cost ratio analysis (percentage of total revenues), 2011–17
Table: Shire’s operating revenue/cost analysis ($m), 2011–17
Table: Exchange rates, 2012
FIGURES
Figure: The PharmaVitae Explorer
Figure: Shire’s prescription pharmaceutical performance, sales ($m) and growth rate (%), 2005–17
Figure: Shire’s financial performance ($m), 2005–17
Figure: Shire’s launch/core/expiry configuration ($m), 2011–17
Figure: Shire’s prescription pharmaceutical sales, by therapy area ($m), 2003–17
Figure: Forecast sales of the Gaucher disease drug market ($m), 2011–17
Figure: Shire’s corporate structure
Figure: Shire’s operating revenue/cost analysis ($m), 2005–17
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
